QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
OTCMKTS:ARTH

Arch Therapeutics - ARTH Stock Forecast, Price & News

$3.16
+0.01 (+0.32%)
(As of 03/28/2023 12:00 AM ET)
Add
Compare
Today's Range
$3.15
▼
$3.30
50-Day Range
$0.03
▼
$7.00
52-Week Range
$2.02
▼
$20.70
Volume
430 shs
Average Volume
1,423 shs
Market Capitalization
$3.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ARTH stock logo

About Arch Therapeutics (OTCMKTS:ARTH) Stock

Arch Therapeutics, Inc. is a development stage biotechnology company, which engages in the development and provision of hemostasis and sealant technology platform. Its product candidates include AC5 Devices, which designed to achieve hemostasis during surgical, wound, and interventional care. The company was founded by Rutledge Ellis-Behnke and Terrence W. Norchi on September 16, 2009 and is headquartered in Framingham, MA.

Receive ARTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arch Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ARTH Stock News Headlines

March 20, 2023 | investing.com
Arch Therapeutics Inc (ARTHD)
March 9, 2023 | finance.yahoo.com
Arch Therapeutics’ AC5® Advanced Wound System Receives Dedicated HCPCS Billing Code from The Centers for Medicare & Medicaid Services
March 28, 2023 | The Oxford Club (Ad)
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
March 7, 2023 | finance.yahoo.com
Arch Therapeutics Announces Addition of Contract Sales Force to Advance Commercialization of AC5® Advanced Wound System in Government Facilities
February 23, 2023 | benzinga.com
Arch Therapeutics Inc Stock (OTC:ARTHD), Earnings Estimates, EPS, and Revenue
January 24, 2023 | msn.com
Wound products developer Arch Therapeutics files for uplisting, $35M offering (update)
January 18, 2023 | finanznachrichten.de
Arch Therapeutics, Inc.: Arch Announces One-for-Two-Hundred Reverse Stock Split in Connection with Application for Uplisting to a National Exchange
January 18, 2023 | finance.yahoo.com
Arch Therapeutics Announces Formation of Medical Advisory Board to Advance Commercialization of AC5® Advanced Wound System
March 28, 2023 | The Oxford Club (Ad)
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
January 17, 2023 | finance.yahoo.com
Arch Announces One-for-Two-Hundred Reverse Stock Split in Connection with Application for Uplisting to a National Exchange
December 5, 2022 | finance.yahoo.com
The Centers for Medicare & Medicaid Services Makes Preliminary Recommendation to Establish New HCPCS Billing Code Dedicated to Arch Therapeutics’ AC5® Advanced Wound System
October 20, 2022 | seekingalpha.com
ARTH Arch Therapeutics, Inc.
October 11, 2022 | finance.yahoo.com
Arch Therapeutics’ AC5® Advanced Wound System to be Presented with Honors at 2022 Symposium on Advanced Wound Care (SAWC) Fall
September 23, 2022 | finance.yahoo.com
Arch Therapeutics Announces First Shipments of AC5® Advanced Wound System Under New Reimbursement Support Program
September 16, 2022 | finance.yahoo.com
Arch Therapeutics Announces Intent to Uplist from OTC to a National Exchange
September 7, 2022 | finance.yahoo.com
Arch Therapeutics Launches Multi-Site Clinical Study for AC5® Advanced Wound System
July 14, 2022 | benzinga.com
Arch Therapeutics (OTC:ARTH), Short Interest Report
July 7, 2022 | finance.yahoo.com
Arch Therapeutics Raises Approximately $3.5 Million in Convertible Note Financing
June 22, 2022 | finance.yahoo.com
Arch Therapeutics Provides Update on Reimbursement Strategy in Additional Selling Channel
May 9, 2022 | finance.yahoo.com
Arch Therapeutics’ Experts in Wound Care Interview Showcases AC5 Self-Assembling Peptide Technology During Live Session at SAWC Spring
April 13, 2022 | finance.yahoo.com
Renowned Wound Care Key Opinion Leaders Presented Arch Therapeutics’ AC5® Advanced Wound System at 2022 Symposium on Advanced Wound Care (SAWC) Spring
April 4, 2022 | finance.yahoo.com
Arch Therapeutics’ AC5® Advanced Wound System to be Presented at 2022 Symposium on Advanced Wound Care (SAWC) Spring
March 14, 2022 | finance.yahoo.com
Arch Therapeutics Partners with Centurion Therapeutics to Expand Access to AC5® Advanced Wound System
January 6, 2022 | finance.yahoo.com
Clinical Evaluation Finds Arch Therapeutics’ AC5® Advanced Wound System Effective in Healing Complex Chronic Wounds in Patients with Previously Unsuccessful Treatments and Significant Comorbidities
January 4, 2022 | finance.yahoo.com
Arch Therapeutics Announces Appointment of Guy Fish to the Board
December 13, 2021 | finance.yahoo.com
Arch Therapeutics Granted Federal Supply Schedule and General Supply Administration Contracts for AC5® Advanced Wound System
December 1, 2021 | finance.yahoo.com
Arch Therapeutics Adds Key Opinion Leader Interview on Diabetic Foot Ulcers to the Experts in Wound Care Program
See More Headlines
Receive ARTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arch Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ARTH Company Calendar

Last Earnings
2/14/2023
Today
3/28/2023
Fiscal Year End
9/30/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ARTH
Previous Symbol
NASDAQ:ARTH
CUSIP
N/A
CIK
1537561
Web
www.archtherapeutics.com
Phone
(617) 431-2313
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-5,280,000.00
Net Margins
-32,842.03%
Pretax Margin
-32,842.03%
Return on Equity
N/A
Return on Assets
-301.47%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.41
Quick Ratio
0.07

Sales & Book Value

Annual Sales
$20,000.00
Price / Sales
197.50
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($3.36) per share
Price / Book
-0.94

Miscellaneous

Outstanding Shares
1,250,000
Free Float
1,132,000
Market Cap
$3.95 million
Optionable
Not Optionable
Beta
0.72

Key Executives

  • Terrence W. Norchi
    Chairman, President & Chief Executive Officer
  • Michael S. Abrams
    Chief Financial Officer & Treasurer
  • Daniel M. Yrigoyen
    Vice President-Sales

Key Competitors

View All Competitors













ARTH Stock - Frequently Asked Questions

How have ARTH shares performed in 2023?

Arch Therapeutics' stock was trading at $0.0260 at the start of the year. Since then, ARTH shares have increased by 12,053.8% and is now trading at $3.16.
View the best growth stocks for 2023 here.

How were Arch Therapeutics' earnings last quarter?

Arch Therapeutics, Inc. (OTCMKTS:ARTH) issued its quarterly earnings data on Tuesday, February, 14th. The biotechnology company reported ($1.44) EPS for the quarter. The biotechnology company earned $0.01 million during the quarter.

What other stocks do shareholders of Arch Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arch Therapeutics investors own include Anavex Life Sciences (AVXL), POET Technologies (POETF), Aptose Biosciences (APTO), Inovio Pharmaceuticals (INO), Actinium Pharmaceuticals (ATNM), SCYNEXIS (SCYX), Bellerophon Therapeutics (BLPH), Sorrento Therapeutics (SRNE), Biocept (BIOC) and Aurinia Pharmaceuticals (AUPH).

What is Arch Therapeutics' stock symbol?

Arch Therapeutics trades on the OTCMKTS under the ticker symbol "ARTH."

How do I buy shares of Arch Therapeutics?

Shares of ARTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arch Therapeutics' stock price today?

One share of ARTH stock can currently be purchased for approximately $3.16.

How much money does Arch Therapeutics make?

Arch Therapeutics (OTCMKTS:ARTH) has a market capitalization of $3.95 million and generates $20,000.00 in revenue each year.

How can I contact Arch Therapeutics?

Arch Therapeutics' mailing address is 235 WALNUT STREET SUITE 6, FRAMINGHAM MA, 01702. The official website for the company is www.archtherapeutics.com. The biotechnology company can be reached via phone at (617) 431-2313 or via email at investors@archtherapeutics.com.

This page (OTCMKTS:ARTH) was last updated on 3/28/2023 by MarketBeat.com Staff